Doctor profile · Federal record
Dr. SANTHOSH AMBIKA, MD
Hematology & Oncology Physician (CMS: HEMATOLOGY/ONCOLOGY) · Hematology (Pathology) Physician · RENO, NV
- NPI 1174747323
- Accepts Medicare
- MIPS 91.6 / 100 · 2023
- 25 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
5423 RENO CORPORATE DR.
RENO, NV 895112250
(775) 329-0873
fax (775) 329-1026 - Mailing address
-
5423 RENO CORPORATE DR
RENO, NV 895112250
Credentials & registration
- NPI registered
- April 2007 — 19 yrs on file
- Profile last updated
- May 22, 2019
- Year of graduation
- 2001 — 25 yrs since
- Specialty taxonomy
- 207RH0003X — NUCC code
- State license (1)
- Nevada #16308
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1174747323. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
73,117
Distinct HCPCS
10
Medicare allowed
$2,443,533
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J9271 |
Injection, pembrolizumab, 1 mg | 20,600 | 25 | $54 | |
J9144 |
Injection, daratumumab, 10 mg and hyaluronidase-fihj | 13,680 | 16 | $48 | |
Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 8,160 | 12 | $0 | |
J9033 |
Injection, bendamustine hcl (treanda), 1 mg | 6,475 | 11 | $14 | |
J0185 |
Injection, aprepitant, 1 mg | 4,420 | 13 | $2 | |
J0897 |
Injection, denosumab, 1 mg | 3,000 | 19 | $23 | |
J0894 |
Injection, decitabine, 1 mg | 2,600 | 15 | $2 | |
J1100 |
Injection, dexamethasone sodium phosphate, 1 mg | 2,266 | 80 | $0 | |
J2469 |
Injection, palonosetron hcl, 25 mcg | 1,700 | 62 | $1 | |
J9041 |
Injection, bortezomib, 0.1 mg | 1,365 | 11 | $5 |
In context: peer comparison
Among 8 peers in this city , average services per provider: 1,102. This provider delivers 66× the peer median.Open Payments
Industry payments received
All-time total
$22,511
Transactions
64
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| ABBVIE INC. | 24 | $18,197.50 | |
| TAIHO ONCOLOGY, INC. | 2 | $1,602.54 | |
| Daiichi Sankyo Inc. | 6 | $1,350.11 | |
| E.R. Squibb & Sons, L.L.C. | 4 | $110.11 | |
| Merck Sharp & Dohme LLC | 4 | $107.15 | |
| Genentech USA, Inc. | 4 | $94.79 | |
| PFIZER INC. | 4 | $78.90 | |
| SOBI, INC | 2 | $77.16 | |
| TerSera Therapeutics LLC | 2 | $65.06 | |
| SpringWorks Therapeutics, Inc. | 2 | $58.26 | |
| Deciphera Pharmaceuticals Inc. | 2 | $55.07 | |
| Astellas Pharma US Inc | 2 | $50.91 | |
| Mirati Therapeutics, Inc. | 2 | $49.99 | |
| ARRAY BIOPHARMA INC | 2 | $49.96 | |
| EMD Serono, Inc. | 2 | $49.88 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
678
Patients
167
Total drug cost
$2,766,384
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Anastrozole | Generic | 103 | 36 | $3,272 |
| Hydroxyurea | Generic | 74 | 18 | $2,582 |
| Levothyroxine Sodium | Generic | 64 | 14 | $443 |
| Acyclovir | Generic | 51 | 16 | $790 |
| Brukinsa (Zanubrutinib) | Brand | 48 | 0 | $565,910 |
| Jakafi (Ruxolitinib Phosphate) | Brand | 47 | 0 | $770,036 |
| Alendronate Sodium | Generic | 39 | 11 | $557 |
| Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen) | Brand | 39 | 16 | $447 |
| Ibrance (Palbociclib) | Brand | 35 | 0 | $547,749 |
| Ondansetron Odt (Ondansetron) | Brand | 35 | 22 | $547 |